Alexion Pharmaceuticals Inc (ALXN) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2014

Earnings Press Release
10-K Annual Report
10-K YoY Changes
Alexion Pharmaceuticals, Inc.
Ticker: ALXN CIK: 899866

Alexion Reports Fourth Quarter and Full Year 2014 Results and Provides Financial Guidance for 2015

- Soliris® (eculizumab) Net Product Sales Increased 44 Percent

to $2.234 Billion -

- Soliris Net Product In-Year Sales Increased 38 Percent

to $2.146 Billion -

- Steady Soliris PNH Growth Worldwide; aHUS Global Launch Progresses -

- Regulatory Submissions for Asfotase Alfa in the U.S., Europe and Japan Completed -

- Three Eculizumab Registration Programs Enrolling in DGF, NMO and MG -

- Two Next-Generation Soliris Phase 1 Trials Underway with ALXN1210 and ALXN5500 -

- 17 Pre-clinical Development Programs Spanning Diverse Modalities and Therapeutic Areas -

Full Year 2014 Financial Highlights:


•	2014 net product sales increased 44 percent to $2.234 billion, compared to $1.551 billion in 2013. Excluding the impact of $88 million for reimbursement of prior year shipments, 2014 net product sales increased 38 percent to $2.146 billion.


•	2014 GAAP EPS increased to $3.26 per share, compared to 2013 GAAP EPS of $1.27 per share.


•	2014 non-GAAP EPS increased 69 percent to $5.21 per share, compared to 2013 non-GAAP EPS of $3.08 per share. Excluding $0.37 per share related to reimbursement of prior year shipments, 2014 non-GAAP EPS increased 57 percent to $4.84 per share.

Fourth Quarter 2014 Financial Highlights


•	Q4 2014 net product sales increased 36 percent to $599 million, compared to $442 million in Q4 2013.


•	Q4 2014 GAAP EPS increased to $0.76 per share, compared to a Q4 2013 GAAP net loss of $0.10 per share.


•	Q4 2014 non-GAAP EPS increased 49 percent to $1.30 per share, compared to Q4 2013 non-GAAP EPS of $0.87 per share.

The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, January 29, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Alexion Pharmaceuticals, Inc..

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/899866/000089986615000016/alxn10k12312014.htm